Weifang

Researchers are evaluating the safety and effectiveness of starting direct oral anticoagulants (DOACs) early versus later in patients who have acute ischemic stroke related to atrial fibrillation and who have undergone emergency endovascular therapy (EVT). This multicenter, prospective, open-label randomized controlled trial focuses on different timings to begin DOAC therapy to improve outcomes and reduce risks after stroke. Patients will be randomly assigned to one of two groups: the early anticoagulation group, which starts DOACs within four days of symptom onset, and the delayed anticoagulation group, which begins DOACs between 5 and 14 days after symptom onset. The study observes these treatment timings after emergency EVT for stroke, assessing their effects on patient safety and stroke recurrence. Participants will be monitored closely for 90 days after treatment to assess outcomes including recurrent ischemic stroke, symptomatic intracranial hemorrhage, and death from any cause. Evaluations include clinical assessments and imaging such as CT or MRI to detect hemorrhagic changes. Researchers will also review medical history, stroke severity, and treatment adherence. The study involves follow-up visits and data collection to ensure thorough safety and efficacy analysis over the three-month period.

Researchers are evaluating the safety and effectiveness of starting direct oral anticoagulants (DOACs) early versus delaying their start in patients who have had an acute ischemic stroke related to atrial fibrillation and developed bleeding in the brain after emergency endovascular treatment. This is a multicenter, open-label, randomized controlled trial focusing on different timings for beginning DOAC therapy to improve patient outcomes after stroke. Participants are assigned to one of two groups: early anticoagulation, where DOACs are started within 4 weeks after stroke symptoms begin, or delayed anticoagulation, where DOACs are started between 4 to 8 weeks after symptom onset. The study compares these two approaches to understand which timing is safer and more effective in managing stroke patients who experienced hemorrhagic transformation after treatment. During the study, patients will be monitored for a composite outcome including recurrent ischemic stroke, symptomatic brain bleeding, and death from any cause within 90 days. Researchers will conduct assessments and follow patients closely during this period to evaluate the effects of the timing of anticoagulant initiation. Participants will be followed up for 90 days to track these outcomes and assess safety and efficacy.